CN1778313A - Medicine for preventing skin superficial fungalinfection and female genital infection - Google Patents
Medicine for preventing skin superficial fungalinfection and female genital infection Download PDFInfo
- Publication number
- CN1778313A CN1778313A CN 200410091162 CN200410091162A CN1778313A CN 1778313 A CN1778313 A CN 1778313A CN 200410091162 CN200410091162 CN 200410091162 CN 200410091162 A CN200410091162 A CN 200410091162A CN 1778313 A CN1778313 A CN 1778313A
- Authority
- CN
- China
- Prior art keywords
- infection
- zinc
- women
- medicine
- genital tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A medicine for preventing and treating the fungal infection of superficial skin and the infection to genetic tract of woman is proportionally prepared from silver peroxide (or oxide), Zn salt, and the pharmacologically acceptable carrier and auxiliary.
Description
Technical field
The present invention relates to antibacterials, particularly be that a kind of control superficial skin fungus that contains silver oxide and zinc salt composition infects and the medicine of women ' s genital tract infection.
Background technology
At present, silver, zinc are as the existing many reports of the application of anti-biotic material.Wherein, the application of silver is with silver ion, coordination compound, complex mostly or with inorganic, organic carrier form, the greatest problem that exists in the application is degeneration, the discoloration problem of silver, and it is desirable not enough to the antibacterial effect such as fungus and mycete etc.
Zinc element is confirmed already in application pharmaceutically, as all effective in cure to wound healing, stomatitis, skin lesion type pimple, pustule, erosive dermatitis etc.Zinc also is a kind of traditional inorganic fungicide.Zinc is as anti-biotic material, and it is inchoate in recent years being paid attention to by people.Though the too late any silver of the antibacterial ability of zinc, zinc antifungal energy force rate silver is strong, and zinc is eager to excel to the more independent silver of the sterilization effect of fungus and mycete with the silver-colored back of making up.
Discover that the oxide of silver also has very strong sterilizing power, and its stable performance does not exist degeneration, discoloration problem.Silver oxide is as the existing report of antibacterial in the prior art, for example U.S. Pat 6436420B1 discloses a kind of method for preparing the argentiferous fabric, this method be with textile impregnation in containing the aqueous solution of dissolved silver nitrate, after dipping a period of time, take out this fabric, and be impregnated in the aqueous solution that contains sodium hydroxide and sodium peroxydisulfate of heat, solution is heated to 95～100 ℃ again, obtain silver-colored anti-biotic material thus.This method is by twice dipping, and for the first time dipping is to make the monovalence silver ion immerse between the fiber of fabric or be deposited on the fiber, and dipping is by the monovalence silver ion is oxidized to silver peroxide (Ag for the second time
4O
4), so that fabric contains silver peroxide and has antibiotic property.
Silver and zinc are compound as anti-biotic material, existing report in the prior art, Chinese patent 00112519.2 discloses a kind of silver zinc combined antimicrobial agent, by aminoacid silver and amino-acid zinc, with and the argent that decompose to generate, zinc oxide is formed the antibiotic property motif material of antibacterial.Though this technology is combined as antibacterial with silver and zinc, its stability has much room for improvement.
Summary of the invention
At the problems referred to above, the purpose of this invention is to provide a kind of control superficial skin fungus infection of silver oxide composition and zinc salt composition and antibacterials of women ' s genital tract infection of containing.
For achieving the above object, the present invention takes following technical scheme: a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection, the active substance that comprises following weight percentage in its pharmaceutical composition composition: silver peroxide or silver oxide 0.001%～20%, zinc salt 0.001%～20%, surplus are carrier and the medicinal adjuvant that allows on the pharmacopedics.
Described zinc salt is selected from zinc sulfate, zinc acetate, zinc lactate, zinc tartrate, zinc gluconate, ethylenediaminetetraacetic acid zinc, malic acid zinc or zinc citrate.
Described carrier and medicinal adjuvant are one or more in excipient, binding agent, disintegrating agent, fluidizer and lubricant and the analog.
Described excipient is selected from one or more in carbomer resin, microcrystalline Cellulose, hydroxypropyl cellulose, sucrose, lactose, glucose, starch, modified starch, xanthan gum, sodium alginate, arabic gum, agar, pectin, gelatin, chitosan and the mannitol.
Described binding agent is selected from one or more in syrup, arabic gum, gelatin, Sorbitol, methylcellulose and the polyvinylpyrrolidone.
Described disintegrating agent is selected from one or more in starch, carboxymethyl cellulose and salt thereof, microcrystalline Cellulose, Polyethylene Glycol, crospolyvinylpyrrolidone, agar and the alginate.
Described fluidizer is selected from one or more in Pulvis Talci, magnesium stearate, calcium stearate and the tripoli.
Described lubricant is selected from one or more in magnesium stearate, sodium laurate and the glycerol.
Described control superficial skin fungus infects and the dosage form of women ' s genital tract infection medicine comprises tablet, powder, gel, lotion, unguentum, membrane, cream, patch, suppository, effervescent tablet, instant, fast disintegrating tablet and foam.
Described women ' s genital tract infection comprises bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, Combination vaginitis, mycoplasma chlamydia infection, gonococcal infection, cervicitis and cervical erosion.
Described superficial skin fungus infects and comprises acne, acne, tineatonsurans or the dandruff, tinea barbae, tinea corporis, tinea cruris, the tinea manuum, tinea pedis or beriberi, tinea favosa, tinea unguium, psoriasis and tinea imbricata.
Prove that by pharmacological testing silver oxide and zinc salt combination have the effect of infection of control superficial skin fungus and women ' s genital tract infection, can be used for preparing the medicine of infection of control superficial skin fungus and women ' s genital tract infection.
The antibacterials that the present invention relates to, its active component is combined by silver oxide and zinc salt.The purpose that adds zinc in the antibacterials of argentiferous zinc composition singly is not in order to improve the weather resisteant of silver, the more important thing is the synergism that is their sterilizations, studies show that, when the proportioning of zinc and silver oxide reaches a timing, its sterilization functions increases greatly, and is as shown in table 1.
Table 1
| NO | Ag% (silver peroxide) | Zn％ | To Candida albicans sterilizing rate % (10 minutes 5.25 * 10 5cfu/ml) |
| 1 | 0.01 | 0 | 94.45 |
| 2 | 0.01 | 0.01 | 99.72 |
| 3 | 0.01 | 0.03 | 99.95 |
| 4 | 0.01 | 0.05 | 99.91 |
| 5 | 0.01 | 0.10 | 99.85 |
| 6 | 0.01 | 0.20 | 99.57 |
| 7 | 0.01 | 0.30 | 98.10 |
| 8 | 0.01 | 0.50 | 97.70 |
| 9 | 0.01 | 1.0 | 97.30 |
The present invention is owing to take above technical scheme, and it has the following advantages: 1, silver-colored zinc combination antibacterials of the present invention, and stronger to the sterilizing ability of all kinds of pathogenic bacterium especially fungus and mycete, sterilization speed is faster; 2, silver-colored zinc combination antibacterials of the present invention, safety is good, and stability is high, is the medicine of a kind of ideal control superficial skin fungus infection and women ' s genital tract infection; 3, silver-colored zinc combination antibacterials of the present invention, processing technology is simple, and the cycle is short, and cost is low.
The specific embodiment
Embodiment 1, contain antibiotic preparation of silver peroxide and zinc composition.
Prepare by following prescription: (specification: the 200mg/ sheet)
Silver peroxide 5g
Zinc citrate 1g
Starch 130g
Hydroxypropyl cellulose 37g
Polyvinylpyrrolidone K30 25g
Magnesium stearate 2g
Add up to 200g
Silver peroxide, zinc citrate medication were sieved, mix with starch, hydroxypropyl cellulose then, form the mixture of homogeneous, adding polyvinylpyrrolidone K30 aqueous solution again granulates, coarse grain is crossed 16 mesh sieves, drying, granulate and mix with magnesium stearate then, again the gained granule is pressed into tablet, it can be dissolved in a certain amount of water during use and uses.
Embodiment 2, contain antibiotic preparation of silver oxide and zinc zinc composition.
Prepare by following prescription: (specification: the 200mg/ sheet)
Silver oxide 0.5g
Zinc lactate 5.0g
Starch 130.0g
Hydroxypropyl cellulose 37.0g
Polyvinylpyrrolidone K30 25.0g
Magnesium stearate 2.5g
Add up to 200.0g
Silver oxide, zinc lactate are crossed 200 order medicines sieve, mix with starch, hydroxypropyl cellulose then, form the mixture of homogeneous, adding polyvinylpyrrolidone K30 aqueous solution again granulates, coarse grain is crossed 16 mesh sieves, drying, granulate and mix with magnesium stearate then, again the gained granule is pressed into tablet, it can be dissolved in a certain amount of water during use and uses.
Embodiment 3, contain the preparation of the antibacterial gel of silver peroxide and zinc composition.
Prepare by following prescription:
Silver peroxide 0.5g
Malic acid zinc 10.0g
Polyethylene Glycol 75.0g
Sodium carboxymethyl cellulose 35.0g
Oleum menthae 5.0ml
Add pure water to 1000.0g
Silver peroxide, malic acid zinc are crossed 200 order medicines sieve and mix homogeneously, mix with sodium carboxymethyl cellulose again, add the Polyethylene Glycol mixing then, add pure water again, stir while adding, continue to add Oleum menthae and stir, add pure water at last to 1000g, the back fill stirs.
Embodiment 4, contain the preparation of the antibacterial gel of silver oxide and zinc composition.
Prepare by following prescription:
Silver oxide 5.0g
Zinc acetate 10.0g
Polyethylene Glycol 60.0g
Sodium carboxymethyl cellulose 40.0g
Oleum menthae 5.0ml
Add pure water to 1000.0g
Silver oxide, zinc acetate are crossed 200 order medicines sieve and mix homogeneously, mix with sodium carboxymethyl cellulose again, add the Polyethylene Glycol mixing then, add pure water again, stir while adding, continue to add Oleum menthae and stir, add pure water at last to 1000g, the back fill stirs.
Embodiment 5, contain the preparation of the antibacterial gel of silver peroxide and zinc composition.
Prepare by following prescription:
Silver peroxide 0.01g
Malic acid zinc 20.0g
Carbomer 75.0g
Carmellose sodium 35.0g
Oleum menthae 5.0ml
Add pure water to 1000.0g
Silver peroxide, malic acid zinc are crossed 200 order medicines sieve and mix homogeneously, mix with sodium carboxymethyl cellulose again, add the carbomer mixing then, add pure water again, stir while adding, continue to add Oleum menthae and stir, add pure water at last to 1000g, the back fill stirs.
Embodiment 6, contain the preparation of the membrane of silver peroxide and zinc composition.
A. with 4 kilograms of polyvinyl alcohol (PVA17～88 1.6 kilogram, PVA25～99 2.4 kilogram) be dissolved in 20 premium on currency, the sodium starch glycol that adds 0.8 kilogram again, stir after the dissolving, add 15 liters of pure water again, it is dissolved fully, add 120 gram sodium laurylsulfates then, add 20 gram silver peroxide micropowders and 10 gram zinc lactate after the stirring and dissolving again, stir and make it to become the uniform aqueous solution that suspends;
B. the aqueous solution with 10%PVA17～99 evenly spreads upon on the horizontal glass plate, after drying under 40 ℃ of conditions, apply 4% nitrocellulosic alcohol (1 volume) ether (2 volume) mixed solution earlier, repaste applies the aqueous solution that the A step is prepared, in 40 ℃ of water-baths, be heated to intensive drying then, be cut into 3 * 4 or 6 * 8 centimeters small pieces then and promptly make the membrane that contains silver peroxide and zinc composition.
Embodiment 7, contain the preparation of the effervescent tablet of silver peroxide and zinc composition.
Prepare by following prescription: (specification: the 100mg/ sheet)
Silver peroxide 0.5g
Zinc tartrate 1.0g
Tartaric acid 15.0g
Sodium bicarbonate 13.0g
Low-substituted hydroxypropyl cellulose 45.0g
Methylcellulose 18.0g
Sodium lauryl sulphate 5.0g
Magnesium stearate 2.5g
Press above-mentioned weight proportion with silver peroxide, zinc tartrate, tartaric acid, sodium bicarbonate, low-substituted hydroxypropyl cellulose, methylcellulose, sodium lauryl sulphate mix homogeneously, make soft material, granulate by 20 mesh sieves, 60 ℃ dry down, reuse 18 mesh sieve granulate, add the magnesium stearate mix homogeneously then, measure tabletting behind its content.
Embodiment 8, contain the preparation of the fast disintegrating tablet of silver oxide and zinc composition.
Prepare by following prescription: (specification: the 100mg/ sheet)
Silver oxide 9.0g
Zinc lactate 1.0g
Lactose 20.0g
Mannitol 60.0g
Hyprolose 7.0g
Magnesium stearate 3.0g
Add up to 100.0g
Silver oxide is crossed the medicine sieve, mix with zinc lactate, lactose, mannitol and hyprolose then, form the mixture of homogeneous, and cross 16 mesh sieves, drying, granulate and mix then with magnesium stearate, be pressed into the fast disintegrating tablet of required form again through low pressure, make 1000 altogether, every 100mg.The fast disintegrating tablet of other content can prepare by ratio or the tabletting weight that changes reactive compound and excipient.
Embodiment 9, contain the preparation of the suppository of silver peroxide and zinc composition.
Prepare by following prescription:
Silver peroxide 14g
Zinc lactate 14g
Glycerol 5g
Glycerin gelatine 67g
Add up to 100g
Silver peroxide, zinc lactate are scattered in the glycerol, join in the glycerin gelatine that has melted fill behind the mixing when mixture is stirred.
Embodiment 10, contain the preparation of the suppository of silver oxide and zinc composition.
Prepare by following prescription:
Silver oxide 20g
Zinc lactate 20g
Glycerol 9g
Glycerin gelatine 51g
Add up to 100g
Silver oxide, zinc lactate are scattered in the glycerol, join in the glycerin gelatine that has melted fill behind the mixing when mixture is stirred.
Embodiment 11, contain the preparation of the ointment of silver oxide and zinc composition.
Prepare by following prescription:
Silver oxide 5g
Zinc lactate 5g
Olive oil 10g
White vaseline 80g
Add up to 100g
Silver oxide and zinc lactate are scattered in the olive oil, join in the white vaseline that has melted fill behind the mixing when mixture is stirred.
Embodiment 12, contain the preparation of the ointment of silver peroxide and zinc composition.
Prepare by following prescription:
Silver peroxide 0.001g
Zinc lactate 0.001g
Olive oil 10.998g
White vaseline 89.000g
Add up to 100.000g
Silver peroxide and zinc lactate are scattered in the olive oil, join in the white vaseline that has melted fill behind the mixing when mixture is stirred.
Embodiment 13, the present invention contain the experiment of the antibacterials clinical treatment woman vagina infection of silver oxide composition and zinc salt composition.
Adopt the suppository that contains silver peroxide and zinc lactate composition of embodiment 9 preparations, clinical experiment treatment woman vagina infects, and its result is shown in table 2,3.
Table 2: the suppository clinical treatment vaginitis result of experiment that contains silver peroxide and zinc lactate composition
| Classification | Candidal vaginitis | Trichomonal vaginitis | Bacterial vaginosis | Add up to | |
| The example number | 36 | 36 | 36 | 108 | |
| Recovery from illness | The example number | 28 | 27 | 33 | 88 |
| ％ | 77.8 | 75.0 | 91.7 | 81.5 | |
| Produce effects | The example number | 6 | 8 | 3 | 17 |
| ％ | 16.7 | 22.2 | 8.3 | 15.7 | |
| Improve | The example number | 1 | 1 | 0 | 2 |
| ％ | 2.8 | 2.8 | 0 | 1.87 | |
| Invalid | The example number | 1 | 0 | 0 | 1 |
| ％ | 2.8 | 0 | 0 | 0.93 | |
| Total effective rate (%) | 97.2 | 100.0 | 100.0 | 99.07 | |
Table 3: the suppository clinical treatment cervicitis result of experiment that contains silver peroxide and zinc lactate composition
| Classification | The example number | Cure | Produce effects | Invalid | Total effective rate (%) | |||
| The example number | ％ | The example number | ％ | The example number | ％ | |||
| Slightly | 32 | 24 | 75.0 | 8 | 25.0 | 0 | 0 | 100.0 |
| Moderate | 32 | 19 | 59.4 | 8 | 25.0 | 5 | 15.6 | 84.4 |
| Severe | 30 | 13 | 43.3 | 10 | 33.3 | 7 | 22.6 | 77.4 |
| Add up to | 94 | 56 | 59.2 | 26 | 27.8 | 12 | 12.7 | 87.5 |
In the clinical experiment process, there is not patient any untoward reaction to occur.
Embodiment 14, the present invention contain the experiment of the antibacterials clinical treatment cutaneous fungal infection of silver oxide and zinc salt composition.
Tried patient's totally 60 examples, women 10 examples of man's 50 examples, tinea corporis and cruris 35 examples wherein, the course of disease 1 thoughtful 5 years; Tinea manus and pedis 25 examples, the course of disease 1 thoughtful 20 years.Adopt the antibacterial gel that contains silver peroxide and malic acid zinc composition of embodiment 3 preparations to carry out the clinical treatment experiment, medication every day 2 times, in 2 weeks of the course of treatment, experimental result is as shown in table 4.
Table 4: the gel clinical treatment cutaneous fungal infection result of experiment that contains silver peroxide and malic acid zinc composition
| Classification | The example number | Cure | Produce effects | Effectively | Invalid | Total effective rate (%) | Fungus clearance rate (%) | ||||
| The example number | ％ | The example number | ％ | The example number | ％ | The example number | ％ | ||||
| Tinea corporis and cruris | 35 | 7 | 20.0 | 8 | 22.9 | 14 | 40 | 6 | 17.1 | 82.9 | 62.9 |
| Tinea manus and pedis | 25 | 4 | 16.0 | 6 | 24.0 | 7 | 28 | 8 | 32.0 | 68.0 | 60.0 |
| Add up to | 60 | 11 | 18.0 | 14 | 23.3 | 21 | 35 | 14 | 23.3 | 76.6 | 61.7 |
Claims (11)
1, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection, the active substance that comprises following weight percentage in its pharmaceutical composition composition: silver peroxide or silver oxide 0.001%～20%, zinc salt 0.001%～20%, surplus are carrier and the medicinal adjuvant that allows on the pharmacopedics.
2, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 1, it is characterized in that: described zinc salt is selected from zinc sulfate, zinc acetate, zinc lactate, zinc tartrate, zinc gluconate, ethylenediaminetetraacetic acid zinc, malic acid zinc or zinc citrate.
3, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 1, it is characterized in that: carrier that allows on the described pharmacopedics and medicinal adjuvant are one or more in excipient, binding agent, disintegrating agent, fluidizer and lubricant and the analog.
4, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 3, it is characterized in that: described excipient is selected from one or more in carbomer resin, microcrystalline Cellulose, hydroxypropyl cellulose, sucrose, lactose, glucose, starch, modified starch, xanthan gum, sodium alginate, arabic gum, agar, pectin, gelatin, chitosan and the mannitol.
5, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 3, it is characterized in that: described binding agent is selected from one or more in syrup, arabic gum, gelatin, Sorbitol, methylcellulose and the polyvinylpyrrolidone.
6, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 3, it is characterized in that: described disintegrating agent is selected from one or more in starch, carboxymethyl cellulose and salt thereof, microcrystalline Cellulose, Polyethylene Glycol, crospolyvinylpyrrolidone, agar and the alginate.
7, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 3, it is characterized in that: described fluidizer is selected from one or more in Pulvis Talci, magnesium stearate, calcium stearate and the tripoli.
8, a kind of medicine of preventing and treating superficial skin fungus infection and women ' s genital tract infection as claimed in claim 3, it is characterized in that: described lubricant is selected from one or more in magnesium stearate, sodium laurate and the glycerol.
9, as claimed in claim 3ly a kind ofly prevent and treat that superficial skin fungus infects and the medicine of women ' s genital tract infection, it is characterized in that: described control superficial skin fungus infects and the dosage form of women ' s genital tract infection medicine comprises tablet, powder, gel, lotion, unguentum, membrane, cream, patch, suppository, effervescent tablet, instant, fast disintegrating tablet and foam.
10, as claim 1 or 9 described a kind of medicines of preventing and treating superficial skin fungus infection and women ' s genital tract infection, it is characterized in that: described women ' s genital tract infection comprises bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, Combination vaginitis, mycoplasma chlamydia infection, gonococcal infection, cervicitis and cervical erosion.
11, as claim 1 or 9 described a kind of medicines of preventing and treating superficial skin fungus infection and women ' s genital tract infection, it is characterized in that: described superficial skin fungus infects and comprises acne, acne, tineatonsurans or the dandruff, tinea barbae, tinea corporis, tinea cruris, the tinea manuum, tinea pedis or beriberi, tinea favosa, tinea unguium, psoriasis and tinea imbricata.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410091162 CN1778313A (en) | 2004-11-22 | 2004-11-22 | Medicine for preventing skin superficial fungalinfection and female genital infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410091162 CN1778313A (en) | 2004-11-22 | 2004-11-22 | Medicine for preventing skin superficial fungalinfection and female genital infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1778313A true CN1778313A (en) | 2006-05-31 |
Family
ID=36768850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410091162 Pending CN1778313A (en) | 2004-11-22 | 2004-11-22 | Medicine for preventing skin superficial fungalinfection and female genital infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1778313A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472126A (en) * | 2009-07-21 | 2011-01-26 | Aidance Skincare & Topical Solutions Llc | Topical formulation comprising zinc oxide and silver (II) oxide |
-
2004
- 2004-11-22 CN CN 200410091162 patent/CN1778313A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472126A (en) * | 2009-07-21 | 2011-01-26 | Aidance Skincare & Topical Solutions Llc | Topical formulation comprising zinc oxide and silver (II) oxide |
| GB2472126B (en) * | 2009-07-21 | 2011-08-03 | Aidance Skincare & Topical Solutions Llc | Topical Formulations Containing Silver (II) Oxide and Zinc Oxide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1198596C (en) | Sustained release formulations for 24 hour release of metoprolol | |
| CN101062055A (en) | Slowly-released type nanometer silver antibacterial gel and the preparing method and the application thereof | |
| CN1899291A (en) | External use antifungal compound composition and its use | |
| CN1742957A (en) | Sangju effervescent tablet for treating common cold | |
| CN1296052C (en) | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate | |
| CN1943564A (en) | Indapamide slow release tablet and its preparing method | |
| CN1729994A (en) | Povidone iodine effervescence tablet for treating milk cow colpitis, its preparation process and application | |
| CN1751577A (en) | Composite sterilizing agent contg. silver and zinc, prepn. method and application thereof | |
| CN1778313A (en) | Medicine for preventing skin superficial fungalinfection and female genital infection | |
| CN1556101A (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1748758A (en) | Dragon's blood gel preparation and its preparing method | |
| CN1698663A (en) | Ring form effervescence dosage and preparation method thereof | |
| CN1883473A (en) | An enteric coated tablet of dulouxetine | |
| CN1833652A (en) | Sustained release composns preparation of Fudosteine and clarithromycin | |
| CN1840010A (en) | Minipill for treating gastric disease and preparation method thereof | |
| CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
| CN1827117A (en) | Sustained release medicament of compound gossypol acetate | |
| CN1273115C (en) | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process | |
| CN109806235A (en) | A kind of Fluconazole piece and preparation method thereof | |
| CN1526384A (en) | Quickly disintegrated fenofibrate oral prepn | |
| CN1711997A (en) | 5-keto-amine pentanoic acid salt externally-applied preparation and production thereof | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN101066252A (en) | Aminoglucose calcium tablet and its prepn process | |
| CN1309376C (en) | Musk slow-controlled release preparation and preparation method thereof | |
| CN100571713C (en) | The new purposes of silver peroxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |